English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The current issue of JAHA features a very welcome article[1][1] on the need for joint reporting of clinical end points and safety events in clinical trials, especially in large, multisite‐multicountry trials. The article refers to a particular trial on acute coronary syndrome,[2][2] the Apixaban

Adverse Events as End Points: The Need to Account for Both Sides of the Same Coin